8-K: PURE Bioscience Reports Reduced Quarterly Loss Amidst Sales Growth and New Dairy Membrane Solution Rollout

PURE Bioscience, Inc. announced its fiscal third quarter 2025 financial results, showing increased net product sales and a reduced net loss for the quarter, alongside the successful demonstration of its SDC technology in commercial dairy plants.

Summary

• For the fiscal third quarter ended April 30, 2025, PURE Bioscience reported net product sales of $489,000, an increase of $49,000 (11.1%) compared to $440,000 in the same quarter of 2024.
• The net loss for the fiscal third quarter decreased significantly to $580,000, down from $857,000 in the prior year's quarter, representing a 32.3% reduction.
• Excluding share-based compensation, the net loss for the quarter was $547,000, an improvement from $825,000 in the comparable period.
• Net loss per share remained at ($0.01) for both fiscal third quarters ended April 30, 2025 and 2024.
• For the nine months ended April 30, 2025, net product sales were $1,435,000, a slight decrease of $48,000 (3.2%) from $1,483,000 in the prior nine-month period.
• The net loss for the nine months ended April 30, 2025, improved to $2,067,000, down from $2,594,000 in the same period of 2024, a 20.3% reduction.
• Net loss per share for the nine months improved to ($0.02) from ($0.03) in the prior year.
• Cash and cash equivalents increased to $540,000 as of April 30, 2025, from $349,000 at July 31, 2024.
• Total liabilities significantly increased to $5,871,000 as of April 30, 2025, from $3,682,000 at July 31, 2024, primarily due to an increase in convertible notes payable to related parties.
• The company's stockholders deficiency widened to $(4,814,000) as of April 30, 2025, from $(2,864,000) at July 31, 2024.

Sentiment

Score: 5

Explanation: The sentiment is mixed. While the company showed positive sales growth and reduced net loss in the most recent quarter, and successfully demonstrated a new product application, the overall financial health remains challenging with increasing liabilities, a widening stockholders' deficiency, and continued reliance on related-party debt for operations. The nine-month sales also saw a slight decline.

Positives

• Net product sales for the fiscal third quarter increased by $49,000 to $489,000, indicating growth in the distribution network.
• The net loss for the fiscal third quarter significantly decreased by $277,000 to $580,000, demonstrating improved cost management.
• Net loss per share for the nine months ended April 30, 2025, improved to ($0.02) from ($0.03) in the prior year.
• The company successfully demonstrated its SDC technology's effectiveness as a dairy membrane solution in full-scale commercial dairy plants.
• Reduced net cash used in operating activities for the nine months ended April 30, 2025, to $(1,559,000) from $(1,938,000) in the prior year, indicating a slower cash burn from operations.
• Cash and cash equivalents increased by $191,000 from the end of the last fiscal year.

Negatives

• Net product sales for the nine months ended April 30, 2025, decreased by $48,000 to $1,435,000, attributed to decreased sales across the end-user network.
• The company continues to operate at a net loss, reporting $(580,000) for the quarter and $(2,067,000) for the nine months.
• Total liabilities increased substantially by $2,189,000 to $5,871,000, driven by a significant increase in convertible notes payable to related parties.
• The stockholders deficiency widened to $(4,814,000), indicating a deteriorating equity position.
• Interest expense, net, for the nine months more than doubled to $(210,000) from $(103,000) in the prior year, reflecting increased debt burden.

Risks

• Failure to implement or otherwise achieve the benefits of proposed business initiatives and plans.
• Challenges in achieving market acceptance of the Company's current and future products and services, including converting successful evaluations and tests into customer orders.
• Inability to maintain relationships with partners and other counterparties.
• Failure to generate sufficient revenues and reduce operating expenses to reach profitability.
• Inability to raise the necessary funding to support continued operations and the implementation of its business plan.
• Challenges in developing effective new products and obtaining required regulatory approvals for SDC-based technology.
• Competitive factors, particularly customer acceptance of SDC-based products which are typically more expensive than existing treatment chemicals.
• Dependence upon third-party vendors for product manufacturing.

Future Outlook

PURE Bioscience plans to continue working closely with its distribution partners in the beverage industry to expand the new membrane treatment solution, leveraging the demonstrated effectiveness of its SDC technology in full-scale commercial dairy plants. The company aims to further reduce operating expenses and generate sufficient revenues to achieve profitability, while also focusing on developing new products and securing necessary regulatory approvals.

Management Comments

• "Our fiscal third quarter year-over-year sales growth continues to progress with our direct customers and distribution network, while we continue to reduce operating expenses."
• "This quarter, we were able to demonstrate that our dairy membrane solution using our SDC technology is effective in full-scale commercial dairy plants."
• "We will continue to work closely with our distribution partners in the beverage industry to expand this new membrane treatment solution."
• "The transformative benefits of using PURE Hard Surface as a membrane treatment bring a more innovative and efficient approach, delivering measurable cost savings."
• "This solution enables dairy and beverage manufacturers to maintain the highest quality standards in the industry, without the trade-offs associated with traditional chemistry."

Industry Context

PURE Bioscience operates in the antimicrobial solutions market, specifically targeting the food and beverage industry with its patented silver dihydrogen citrate (SDC) technology. The successful demonstration of their dairy membrane solution positions them to address a critical need for effective and cost-saving sanitation in dairy and beverage manufacturing, potentially disrupting traditional chemical treatment methods. This aligns with broader industry trends towards safer, more efficient, and environmentally conscious antimicrobial solutions.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess the company's performance against global benchmarks or industry standards. The focus is on internal financial performance and the technical validation of their SDC technology in a new application area (dairy membrane treatment).

Related Party Transactions

• The company has convertible notes payable to related parties, which increased by $1,950,000 to $4,899,000 as of April 30, 2025.
• Net proceeds from note payable to related parties amounted to $1,750,000 for the nine months ended April 30, 2025.

Stakeholder Impact

• Shareholders: The widening stockholders' deficiency and continued net losses indicate ongoing dilution risk or value erosion, despite some operational improvements. The reliance on related-party debt could also impact future equity financing terms.
• Customers: The successful demonstration of the dairy membrane solution and its availability (PURE Hard Surface) offers potential cost savings and improved quality standards for dairy and beverage manufacturers, which is a positive for customers.
• Employees: The company's focus on reducing operating expenses could imply continued cost control measures that might affect employees, though no specific details are provided.
• Creditors (Related Parties): Related parties are providing significant financing through convertible notes, indicating their continued support but also increasing the company's debt burden.

Next Steps

• Continue to work closely with distribution partners in the beverage industry to expand the new dairy membrane treatment solution.
• Focus on generating sufficient revenues and reducing operating expenses to achieve profitability.
• Develop effective new products and obtain required regulatory approvals for SDC-based technology.

Key Dates

Recommendation

Keywords

PURE Bioscience, SDC antimicrobial, silver dihydrogen citrate, antimicrobial technology, food and beverage industry, dairy membrane solution, financial results, quarterly report, SEC filing, OTCQB: PURE, biotechnology, chemical safety, pathogen control